The Centers for Medicare & Medicaid Services on Tuesday morning announced the must-anticipated list of the first 10 drugs selected for Medicare price negotiation under the Inflation Reduction Act.

The list includes Eliquis, a Bristol-Myers Squibb drug to prevent blood clots used by more than 3.7 million people on Medicare in the year ending May 2023 at a cost of $16.4 billion to the program, and Xarelto, another blood thinner, made by Johnson & Johnson that is used by more than 1.3 million people on Medicare at a cost to the program of more than $6 billion.

Diabetes drugs Jardiance (Boehringer Ingelheim), Januvia (Merck), Farxiga (AstraZeneca) and Fiasp and Novolog (Novo Nordisk) are on the list, as are Enbrel (Amgen) and Stelara (Janssen), drugs used to treat rheumatoid arthritis, psoriasis and Crohn’s disease. Entresto, a Novartis drug used to treat types of heart failure and Imbruvica, an AbbVie drug that treats blood cancers, are also on the list.

Complete your profile to continue reading and get FREE access to, part of your ALM digital membership.

Your access to unlimited content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events.
  • Access to other award-winning ALM websites including and

Already have an account?


© 2023 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

BenefitsPRO Broker Expo 2024Event

The premier educational and networking event for employee benefits brokers and agents.

Get More Information


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including and
  • Exclusive discounts on and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.